Sinopharm Wuhan Blood Products Co., Ltd.

Sinopharm Wuhan Blood Products Co., Ltd. was established on September 30, 2016. It is a high-tech biopharmaceutical enterprise integrating research and development, production, and operation of blood products, and is one of the *** blood product manufacturing enterprises in China. The company has internationally standardized blood product production lines. At present, it has 11 plasma collection stations in Hubei, Hunan, Shanxi, and Hainan provinces, covering 27 counties (cities). It currently has 9 varieties and 19 specifications of products, including human albumin, intravenous human immunoglobulin (pH4), rabies human immunoglobulin, tetanus human immunoglobulin, and hepatitis B human immunoglobulin, all of which have received good market response and reputation. The company has a high-quality professional team for the management, production, and research and development of blood products, undertakes multiple major projects such as the National "863" Program, the Hubei Provincial Major Science and Technology Innovation Program, and the Wuhan International Science and Technology Cooperation Program, and actively carries out various domestic and international exchanges and cooperation. During the period when the "SARS" virus was raging, it took the lead in China in successfully developing a * specific therapeutic drug against SARS coronavirus: SARS immunoglobulin for intravenous injection. Adhering to the purpose of "facing society, serving the people, quality ***, reputation ***," and taking "product quality is the life of the enterprise, and the users are our own relatives" as its quality policy, the company regards quality as the life of the enterprise, establishes a complete quality inspection organization and a strict quality assurance system in accordance with GMP and GSP requirements, and implements total quality management within the enterprise.